Population pharmacokinetic and pharmacodynamic properties of intramuscular quinine in tanzanian children with severe falciparum malaria

Ilse Hendriksen, Deogratius Maig, Martha Lemnge, George Mtove, Samwel Gesase, Hugh Reyburn, N LINDEGARDH, Nicholas Day, Lorenz Von Seidlein, Arjen Dondorp, J TARNING, N WHITE

    Research output: Contribution to journalArticle

    Abstract

    Although artesunate is clearly superior, parenteral quinine is still used widely for the treatment of severe malaria.A loading-dose regimen has been recommended for 30 years but is still often not used.A population pharmacokinetic study was conducted with 75 Tanzanian children aged 4 months to 8 years with severe malaria who received quinine intramuscularly; 69 patients received a loading dose of 20 mg quinine dihydrochloride (salt)/kg of body weight.Twenty-one patients had plasma quinine concentrations detectable at baseline.A zero-order absorption model with one-compartment disposition pharmacokinetics described the data adequately.Body weight was the only significant covariate and was implemented as an allometric function on clearance and volume parameters.Population pharmacokinetic parameter estimates (and percent relative standard errors [%RSE]) of elimination clearance, central volume of distribution, and duration of zero-order absorption were 0.977 liters/h (6.50%), 16.7 liters (6.39%), and 1.42 h (21.5%), respectively, for a typical patient weighing 11 kg.Quinine exposure was reduced at lower body weights after standard weight-based dosing; there was 18% less exposure over 24 h in patients weighing 5 kg than in those weighing 25 kg.Maximum plasma concentrations after the loading dose were unaffected by body weight.There was no evidence of dose-related drug toxicity with the loading dosing regimen.Intramuscular quinine is rapidly and reliably absorbed in children with severe falciparum malaria.Based on these pharmacokinetic data, a loading dose of 20 mg salt/kg is recommended, provided that no loading dose was administered within 24 h and no routine dose was administered within 12 h of admission.(This study has been registered with Current Controlled Trials under registration number ISRCTN 50258054.).
    Original languageEnglish
    Pages (from-to)775-783
    Number of pages9
    JournalAntimicrobial Agents and Chemotherapy
    Volume57
    Issue number2
    DOIs
    Publication statusPublished - Feb 2013

    Fingerprint Dive into the research topics of 'Population pharmacokinetic and pharmacodynamic properties of intramuscular quinine in tanzanian children with severe falciparum malaria'. Together they form a unique fingerprint.

    Cite this